Related Experiment Videos
Topotecan: weighing in when there are many options
Richard T Penson1, Michael V Seiden
1Department of Hematology and Oncology, Massachusetts General Hospital, Boston, Massachusetts 02114, USA. rpenson@partners.org
The Oncologist
|October 27, 2005
Summary
Full-dose topotecan shows comparable efficacy and manageable toxicity as second-line treatment for small cell lung and ovarian cancers. Its role in ovarian cancer is less clear due to numerous alternative therapies.
Area of Science:
- Medical Oncology
- Clinical Pharmacology
Background:
- Review of topotecan's efficacy and toxicity in second-line treatment for small cell lung cancer (SCLC) and ovarian cancer.
- Focus on full-dose topotecan at U.S. Food and Drug Administration-approved dosage and schedule.
- Analysis of large, homogeneous patient populations with prior platinum exposure.
Discussion:
- Topotecan demonstrates comparable activity to other approved agents in SCLC and ovarian cancer.
- Identifies a well-defined and manageable toxicity profile for topotecan.
- Highlights the challenge in defining topotecan's optimal role in recurrent ovarian cancer due to a growing list of alternative agents.
Key Insights:
- Topotecan offers palliative hope for recurrent SCLC.
- Topotecan's utility in recurrent ovarian cancer is uncertain amidst numerous treatment options.
- Emphasizes the need to prioritize "clinical benefit" and patient-reported outcomes over radiologic or marker response in palliative care.
Outlook:
- Further research may clarify topotecan's specific niche in ovarian cancer management.
- The review serves as a comprehensive resource on topotecan's established role.
- Shifts focus towards patient-centered endpoints in palliative cancer therapy.